Junhui Sun^*1, Guanhui Zhou^*1, Xiaoxi Xie^†, Wenjiang Gu^‡, Jing Huang^§, Dedong Zhu^¶, Wenhao Hu^#, Qinming Hou^**, Changsheng Shi^††, Tiefeng Li^‡‡ , Xin Zhang^§§, Wenbin Ji^¶¶, Shihong Ying^§§, Zhiyi Peng^§§, Jian Zhou^##, Zhihai Yu^***, Jiansong Ji^†††, Haijun Du^‡‡‡, Xiaohua Guo^§§§, Jian Fang^¶¶¶, Jun Han^###, Huanhai Xu^****, Zhichao Sun^††††, Wenqiang Yu^‡‡‡‡, Guoliang Shao^§§§§, Xia Wu^¶¶¶¶ ,Hongjie Hu^¶¶¶¶ , Ling Li^#, Jiaping Zheng^§§§§, Jun Luo^§§§§, Yutang Chen^§§§§, Guohong Cao^####, Tingyang Hu^‡‡‡‡

Oncology Research, Vol.28, No.1, pp. 75-94, 2020, DOI:10.3727/096504019X15662966719585

Abstract The purpose of this study was to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Chinese hepatocellular carcinoma (HCC) patients and the prognostic factors for treatment response as well as survival. A total of 275 HCC patients were included in this prospective study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST), and progression-free survival (PFS) as well as overall survival (OS) were determined. Liver function and adverse events (AEs) were assessed before and after DEB-TACE operation. Complete response (CR), partial response (PR), and objective response… More >

Zhiyi Peng^*1, Guohong Cao^†1, Qinming Hou^‡, Ling Li^§, Shihong Ying^*, Junhui Sun^¶, Guanhui Zhou^¶, Jian Zhou^#, Xin Zhang^*, Wenbin Ji^**, Zhihai Yu^††, Tiefeng Li^‡‡, Dedong Zhu^§, Wenhao Hu^§§, Jiansong Ji^¶¶, Haijun Du^##, Changsheng Shi^***, Xiaohua Guo^†††, Jian Fang^‡‡‡, Jun Han^§§§, Wenjiang Gu^¶¶¶, Xiaoxi Xie^###, Zhichao Sun^****, Huanhai Xu^††††, Xia Wu^‡‡‡‡, Tingyang Hu^§§§§, Jing Huang^¶¶¶¶, Hongjie Hu^‡‡‡‡, Jiaping Zheng^####, Jun Luo^####, Yutang Chen^####, Wenqiang Yu^§§§§, Guoliang Shao^####

Oncology Research, Vol.28, No.3, pp. 249-271, 2020, DOI:10.3727/096504019X15766663541105

Abstract This study aimed to investigate the efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization (DEB-TACE) in treating Chinese patients with liver cancer. A total of 367 liver cancer patients from 24 medical centers were consecutively enrolled in this multiple-center, prospective cohort study, including 275 hepatocellular carcinoma (HCC) cases, 37 intrahepatic cholangiocarcinoma (ICC) cases, and 55 secondary liver cancer cases. All the patients received CalliSpheres^® DEB-TACE treatment. Treatment response, overall survival (OS), change of liver function, and adverse events (AEs) were assessed. DEB-TACE treatment achieved 19.9% complete response (CR) and 79.6% objective response rate (ORR),… More >

Yaohong Liu, Wensou Huang, Mingji He, Hui Lian, Yongjian Guo, Jingjun Huang, Jingwen Zhou, Kangshun Zhu

Oncology Research, Vol.27, No.5, pp. 565-573, 2019, DOI:10.3727/096504018X15313896322888

Abstract This study aimed to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Barcelona Clinic Liver Cancer (BCLC) stage C liver cancer patients. In 39 patients with BCLC stage C liver cancer, after the first cycle of DEB-TACE, 2 (5.1%) and 24 (61.5%) patients achieved complete response (CR) and partial response (PR) to give an overall objective response rate (ORR) of 66.7%. With respect to the second cycle of therapy, the ORR was higher in patients receiving DEB-TACE compared with those receiving cTACE (57.1% vs. 11.1%). After the first cycle of… More >